The Paradox of Beta-Adrenergic Blockade in Hypertension
The effects of long-term treatment with propranolol, a beta-adrenergic blocking drug, were determined in 19 hypertensive patients (five with renal arterial disease, two with renal parenchymal disease, and 12 with essential hypertension) whose vascular disease was of mild to moderate severity. The drug reduced arterial pressure in 16 patients during 32 weeks of treatment (average); daily dose was 180 mg (average). No side effects required discontinuance of treatment. Orthostatic hypotension did not occur, an unusual finding for an antihypertensive drug which acts to inhibit autonomic neural function. In seven patients, hemodynamic studies, performed during treatment (after 10 months, average), confirmed reduction of arterial pressure and heart rate, and demonstrated associated diminution of cardiac output and increased peripheral resistance.
- Drug treatment of hypertension
- Essential hypertension
- Renal parenchymal disease
- Renovascular hypertension
- Cardiac output
- © 1968 American Heart Association, Inc.